HCV Treatment for HIV-Coinfected Patients — Getting Better All the Time

Two open-label studies confirm that a once-daily combination of sofosbuvir plus either ledipasvir or daclatasvir cures hepatitis C virus infection in most such patients.

Due to shared transmission routes, hepatitis C virus (HCV) affects many people living with HIV infection. Despite better HIV treatment options, HCV continues to be a major cause of morbidity and mortality in such individuals. The newer HCV treatment regimens have been proven efficacious and well tolerated in HIV-uninfected patients, but more data are needed regarding coinfected individuals, given the significant drug interactions between antiretrovirals and anti-HCV medications.

Now, in two manufacturer-supported, open-label trials, researchers have examined the efficacy of once-daily combination regimens involving the nucleotide analog inhibitor sofosbuvir plus one of two FDA-approved NS5A inhibitors — ledipasvir (S/L; n=335; 55% treatment-…

Reviewing Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

HCV Treatment for HIV-Coinfected Patients — Getting Better All the Time

Topics

Reviewing Author